Get started
Work

1036O Relatlimab (RELA) + nivolumab (NIVO) vs. NIVO in previously untreated metastatic or unresectable melanoma: Additional efficacy in RELATIVITY-047

Year: 2021
Type: article
DOI: 10.1016/j.annonc.2021.08.1421
Authors: F.S. Hodi, H.A. Tawbi, E.J. Lipson, D. Schadendorf, P.A. Ascierto, L. Matamala, E.C. Gutiérrez, P. Rutkowski, H.J. Gogas, C.D. Lao, J.J. De Menezes, S. Dalle, A. Arance, J.J. Grob, L. Toms, K. Jonczak, A.M. Sobiesk, G.V. Long
Institutions: Dana-Farber Cancer Institute, The University of Texas MD Anderson Cancer Center, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Essen University Hospital, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Fundación Arturo López Pérez, The Maria Sklodowska-Curie National Research Institute of Oncology, National and Kapodistrian University of Athens, University of Michigan, Michigan Medicine, U-M Rogel Cancer Center, Hospices Civils de Lyon, Centre de Recherche en Cancérologie de Lyon, Hospital Clínic de Barcelona, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Aix-Marseille Université, Hôpital de la Timone, Bristol-Myers Squibb (United States), The University of Sydney, Melanoma Institute Australia
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: bronze
OpenAlex ID: W3202967178
FWCI: 0.408
Cites:
Cited by: 5
Related to: 10